Therapeutic targeting of 3′, 5′-cyclic nucleotide phosphodiesterases: inhibition and beyond

GS Baillie, GS Tejeda, MP Kelly - Nature reviews Drug discovery, 2019 - nature.com
Phosphodiesterases (PDEs), enzymes that degrade 3′, 5′-cyclic nucleotides, are being
pursued as therapeutic targets for several diseases, including those affecting the nervous …

The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice

JF Cryan, C Mombereau, A Vassout - Neuroscience & Biobehavioral …, 2005 - Elsevier
Since its introduction almost 20 years ago, the tail suspension test has become one of the
most widely used models for assessing antidepressant-like activity in mice. The test is based …

Role of phosphodiesterases in the pathophysiology of neurodevelopmental disorders

S Delhaye, B Bardoni - Molecular Psychiatry, 2021 - nature.com
Phosphodiesterases (PDEs) are enzymes involved in the homeostasis of both cAMP and
cGMP. They are members of a family of proteins that includes 11 subfamilies with different …

Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents

C Lugnier - Pharmacology & therapeutics, 2006 - Elsevier
Cyclic nucleotide phosphodiesterases (PDEs), which are ubiquitously distributed in
mammalian tissues, play a major role in cell signaling by hydrolyzing cAMP and cGMP. Due …

In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice

JF Cryan, C Mombereau - Molecular psychiatry, 2004 - nature.com
The ability to modify mice genetically has been one of the major breakthroughs in modern
medical science affecting every discipline including psychiatry. It is hoped that the …

The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior

HD Schmidt, RS Duman - Behavioural pharmacology, 2007 - journals.lww.com
Major depressive disorder (MDD) is characterized by structural and neurochemical changes
in limbic structures, including the hippocampus, that regulate mood and cognitive functions …

Keynote review: phosphodiesterase-4 as a therapeutic target

MD Houslay, P Schafer, KYJ Zhang - Drug discovery today, 2005 - Elsevier
Cyclic AMP (cAMP) is a key second messenger in all cells. It is compartmentalized within
cells and its levels are controlled, as a result of spatially discrete signaling cassettes …

Behavioral phenotypes of Disc1 missense mutations in mice

SJ Clapcote, TV Lipina, JK Millar, S Mackie, S Christie… - Neuron, 2007 - cell.com
To support the role of DISC1 in human psychiatric disorders, we identified and analyzed two
independently derived ENU-induced mutations in Exon 2 of mouse Disc1. Mice with …

The DISC locus in psychiatric illness

JE Chubb, NJ Bradshaw, DC Soares, DJ Porteous… - Molecular …, 2008 - nature.com
The DISC locus is located at the breakpoint of a balanced t (1; 11) chromosomal
translocation in a large and unique Scottish family. This translocation segregates in a highly …

Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application

MJ Millan - Pharmacology & therapeutics, 2006 - Elsevier
Major depression is a debilitating and recurrent disorder with a substantial lifetime risk and a
high social cost. Depressed patients generally display co-morbid symptoms, and depression …